其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Amoscanate CAS Registry Number: 26328-53-0 4-硝基-4'-异硫氰基二苯胺

CAS Name: 4-Isothiocyanato-N-(4-nitrophenyl)benzeneamine
Additional Names: isothiocyanic acid p-(p-nitroanilino)phenyl ester; 4-isothiocyanato-4'-nitrodiphenylamine; nithiocyaminePercent Compos...
Literature References: Analog of nitroscanate, q.v. Prepn: K. Antos et al., DE 1932690 (1970 to Cesk. Akad. Ved), C.A. 72, 100265 (1970); S. Rajappa et al., J. Chem. Soc. Perkin Trans. 1 1979, 2001; N. Viswanathan, R. C. Desai, Indian J. Chem. 20B, 308 (1981). Anthelmintic activity: H. P. Striebel, Experientia 32, 457 (1976); K. R. Middleton et al., ibid. 35, 243 (1979); H. G. Sen, B. N. Deb, Am. J. Trop. Med. Hyg. 30, 992 (1981). HPLC determn in human plasma: W. M. Kofi-Tsekpo, C. W. Karekezi, Drugs Exp. Clin. Res. 14, 31 (1988). Clinical pharmacology: A. B. Vaidya et al., Br. J. Clin. Pharmacol. 4, 463 (1977). Mutagenicity study: B. S. Reddy et al., Antimicrob. Agents Chemother. 22, 707 (1982). Brief review: J. I. Bruce, Int. J. Parasitol. 17, 131-140 (1987).

Cargutocin CAS Registry Number: 33605-67-3 卡古缩宫素

CAS Name: 1-Butanoic acid-7-glycine-1,6-dicarbaoxytocin
Additional Names: 1-butyric acid-6-(L-2-aminobutyric acid)-7-glycineoxytocin; 7-glycine-1,6-aminosuberic acid-oxytocin; [Gly7,Asu1,6]oxyt...
Literature References: Analog of oxytocin, q.v. Prepn: S. Sakakibara et al., DE 2056298; eidem, US 3749705 (1971, 1973 both to Yoshitomi). Synthesis and uterotonic activity: T. Yamanaka, S. Sakakibara, Bull. Chem. Soc. Jpn. 47, 1228 (1974). Pharmacological and biochemical properties: T. Oka et al., Jpn. J. Pharmacol. 25, 15 (1975). Comparison with prostaglandin F2a as oxytocic: T. Hashimoto, Iryo 30, 1121 (1976), C.A. 87, 554e (1977). Distribution, metabolism, excretion: Y. Kato et al., Iyakuhin Kenkyu 12, 433 (1981), C.A. 95, 126386k (1981). Teratogenicity studies: Y. Hamada et al., ibid. 10, 26, 41 (1979), C.A. 91, 639u, 83856m (1979).

Oxiracetam CAS Registry Number: 62613-82-5 奥拉西坦

CAS Name: 4-Hydroxy-2-oxo-1-pyrrolidineacetamide
Additional Names: 2-(4-hydroxypyrrolidin-2-on-1-yl)acetamide; hydroxypiracetamTrademarks: Neuractiv (Novartis); Neuromet (SKB)
Percent Compos...
Literature References: Analog of piracetam, q.v., with psychostimulant activity. Prepn: G. Pifferi, M. Pinza, DE 2635853; eidem, US 4118396 (1977, 1978 both to I.S.F.); eidem, Farmaco Ed. Sci. 32, 602 (1977). Effect on learning and memory in animals and prepn of enantiomers: S. Banfi et al., ibid. 39, 16 (1984). Effect in animals with cerebral impairment: S. Banfi et al., Pharmacol. Res. Commun. 16, 67 (1984). Pharmacokinetics in humans: E. Perucca et al., Eur. J. Drug Metab. Pharmacokinet. 9, 267 (1984). Clinical evaluation in organic brain syndrome: B. Saletu et al., Neuropsychobiology 13, 44 (1985).

Tafenoquine CAS Registry Number: 106635-80-7 他非诺喹

CAS Name: N4-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine
Additional Names: 8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[3-(trifluoromet...
Literature References: Analog of primaquine, q.v. Prepn: P. Blumbergs, M. P. LaMontagne, US 4617394 (1986 to U.S. Sec. Army); M. P. LaMontagne et al., J. Med. Chem. 32, 1728 (1989). HPLC determn in blood and plasma: D. A. Kocisko et al., Ther. Drug Monit. 22, 184 (2000). Metabolism: O. R. Idowu et al., Drug Metab. Dispos. 23, 1 (1995). Clinical pharmacokinetics: M. D. Edstein et al., Br. J. Pharmacol. 52, 663 (2001). Clinical evaluation in prevention of malaria relapse: D. S. Walsh et al., J. Infect. Dis. 180, 1282 (1999); in malaria prophylaxis: B. Lell et al., Lancet 355, 2041 (2000); B. R. Hale et al., Clin. Infect. Dis. 36, 541 (2003).

Sulprostone CAS Registry Number: 60325-46-4 硫前列酮

CAS Name: (5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxy-1-butenyl]-5-oxocyclopentyl]-N-(methylsulfonyl)-5-heptenamideTrademarks: Nalador (Schering AG)
Percent Composition: C 59.34...
Literature References: Analog of prostaglandin E2, q.v., with uterine stimulant activity. Prepn: J. Bindra, M. R. Johnson, DE 2355540 (1974 to Pfizer), C.A. 81, 49330u (1974); eidem, US 4024179 (1977 to Pfizer). Antifertility effects: H. Hess et al., Experientia 33, 1076 (1977). Influence on platelet function: R. C. Briel, T. H. Lippert, Adv. Prostaglandin Thromboxane Res. 6, 351 (1980). Biological action and half-life: eidem, Prostaglandins Med. 6, 1 (1981). Induction of abortion: K. Schmidt-Gollwitzer, Int. J. Fertil. 26, 86 (1981).

Carboprost CAS Registry Number: 35700-23-3 卡前列素

CAS Name: (5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-15-methylprosta-5,13-dien-1-oic acid
Additional Names: 7-[3,5-dihydroxy-2-(3-hydroxy-3-methyl-1-octenyl)cyclopentyl]-5-heptenoic acid; (15S)-15-...
Literature References: Analog of prostaglandin F2a, q.v. Prepn: G. L. Bundy et al., DE 2121980; G. L. Bundy, US 3728382 (1971, 1973 both to Upjohn); eidem, Ann. N.Y. Acad. Sci. 180, 76 (1971); E. W. Yankee et al., J. Am. Chem. Soc. 96, 5865 (1974). Biological activity: J. R. Weeks et al., J. Pharmacol. Exp. Ther. 186, 67 (1973). Mechanism of action: A. I. Csapo, M. O. Pulkkinen, Prostaglandins 18, 479 (1979). Clinical studies: P. C. Schwallie, K. R. Lamborn, J. Reprod. Med. 23, 289 (1979); M. P. Mapa et al., Int. J. Gynaecol. Obstet. 20, 125 (1982). Teratological study: G. M. Szczech et al., Adv. Prostaglandin Thromboxane Res. 4, 157 (1978).

Oxantel CAS Registry Number: 36531-26-7 奥克生太

CAS Name: (E)-3-[2-(1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinyl)ethenyl]phenol
Additional Names: (E)-m-[2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl]phenol; 1-methyl-1,4,5,6-tetrahydro-2-[2...
Literature References: Analog of pyrantel, q.v., with activity vs whipworms (Trichuris spp.). Prepn: J. W. Mc Farland, ZA 6804589 corresp to US 3579510 and US 3708584 (1968, 1971, 1973 all to Pfizer). Synthesis and evaluation in whipworm control: J. W. Mc Farland, H. L. Howes J. Med. Chem. 15, 365 (1972). Evaluation vs Trichuris in dogs: H. L. Howes, Proc. Soc. Exp. Biol. Med. 139, 394 (1972). Efficacy vs T. trichiuris in humans: E. L. Lee et al., Am. J. Trop. Med. Hyg. 25, 563 (1976); vs T. suis in swine: M. Robinson, Vet. Parasitol. 5, 223 (1979). Anthelmintic effects of combination with pyrantel pamoate: B. Sinniah, D. Sinniah, Ann. Trop. Med. Parasitol. 75, 315 (1981).

Rescimetol CAS Registry Number: 73573-42-9 瑞西美托

CAS Name: [3b,16b,17a,18b,20a]-18-[[(2E)-3-(4-Hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]oxy]-11,17-dimethoxyyohimban-16-carboxylic acid methyl ester
Additional Names: methyl O-(4-hydroxy-3-meth...
Literature References: Analog of rescinnamine. Prepn: BE 782661 corresp to T. Kametani, US 3898215 (1972, 1975 both to Nippon Chemiphar); T. Kametani et al., J. Med. Chem. 15, 686 (1972). Mass spectrum: eidem, J. Chem. Soc. Perkin Trans. 1 1975, 932. Antihypertensive activity: H. Kato et al., Jpn. J. Pharmacol. 27, 87 (1977). Effects on respiration, cardiovascular system, renal function: T. Kamishiro et al., Oyo Yakuri 20, 441 (1980), C.A. 96, 28430w (1982). Toxicity study: T. Fukuda et al., ibid. 18, 71 (1979), C.A. 92, 104392v (1980).

Epirubicin CAS Registry Number: 56420-45-2 表阿霉素

CAS Name: (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
Additional Names: 3-glycolo...
Literature References: Analog of the anthracycline antibiotic doxorubicin, q.v., differing only in the position of the C-4 hydroxy group of the sugar moiety. Prepn: F. Arcamone et al., DE 2510866; eidem, US 4058519 (1975, 1977 both to Soc. Farmaceut. Italia); eidem, J. Med. Chem. 18, 703 (1975); S. Penco, Process Biochem. 15(5), 12 (1980). Purification: E. Oppici et al., BE 898506; eidem, GB 2133005 (both 1984 to Farmitalia Carlo Erba). Comparison with doxorubicin of in vitro activity: A. Di Marco et al., Cancer Res. 36, 1962 (1976). Tissue distribution: C. Italia et al., Br. J. Cancer 47, 545 (1983); F. Arcamone et al., Cancer Chemother. Pharmacol. 12, 157 (1984). HPLC determn in biological fluids: P. E. Deesen, B. Leyland-Jones, Drug Metab. Dispos. 12, 9 (1984); G. Cassinelli et al., ibid. 506. Clinical trials in solid tumors: K. Kolaric et al., J. Cancer Res. Clin. Oncol. 106, 148 (1983). Review of activity in experimental tumors: A. Goldin et al., Invest. New Drugs 3, 3-21 (1985). Review of pharmacology and clinical efficacy: F. Ganzina, Cancer Treat. Rev. 10, 1-22 (1983); R. J. Cersosimo, W. K. Hong, J. Clin. Oncol. 4, 425-439 (1986); P. Hurteloup, F. Ganzina, Drugs Exp. Clin. Res. 13, 233-246 (1986). Review of epirubicin and other anthracycline antineoplastics: R. B. Weiss et al., Cancer Chemother. Pharmacol. 18, 185-97 (1986).

Stavudine CAS Registry Number: 3056-17-5 司他夫定

CAS Name: 2',3'-Didehydro-3'-deoxythymidine
Additional Names: 1-(2,3-dideoxy-b-glycero-pent-2-enofuranosyl)thymine; 3'-deoxy-2'-thymidinene; D4TTrademarks: Zerit (BMS)
Percent Composition: C...
Literature References: Analog of thymidine, q.v.; reverse transcriptase inhibitor. Prepn: J. P. Horwitz et al., J. Org. Chem. 31, 205 (1966); J. W. Beach et al., ibid. 57, 3887 (1992). Large scale production: J. E. Starrett et al., EP 334368; eidem, US 5130421 (1989, 1992 both to Bristol-Myers). In vitro activity against HIV and toxicology: M. M. Mansuri et al., Antimicrob. Agents Chemother. 34, 637 (1990). Mechanism of action study: H.-T. Ho, M. J. M. Hitchcock, ibid. 33, 844 (1989). Disposition and metabolism: E. M. Cretton et al., ibid. 37, 1816 (1993). Clinical pharmacokinetics: M. N. Dudley et al., J. Infect. Dis. 166, 480 (1992). HPLC determn in plasma and urine: J. S. Janiszewski et al., J. Chromatogr. 577, 151 (1992). Clinical evaluation in AIDS and ARC: M. J. Browne et al., J. Infect. Dis. 167, 21 (1993).